mAbs

Question 1

Bezlotoxumab

Answer 1

C.Difficile toxin B (used in multiple recurred disease >2)

Question 2

Vedolizumab

Question 3

Eculizumab

Question 4

Bevacizumab

Question 5

Trastuzumab

Answer 5

HER2 receptor aka Herceptin

Question 6

Tocilizumab

Answer 6

anti-IL-6

Question 7

Baricitinib

Answer 7

JAK-1/2 inhibitor

Question 8

Remdesivir

Answer 8

inhibits RNA-dependent RNA polymerase

Question 9

Ipilimumab

Answer 9

cytotoxic T lymphocyte associated antigen 4 (CTLA-4)

Question 10

Osimertinib

Answer 10

EGFR TKI in palliative EGFR mut NSCLC and EGFR T790M mutation (Rash most common SE)

Question 11

Ramucirumab

Answer 11

anti-VEGFR2 (anti-angiogenesis) in 2nd line gastric Ca (palliative intent)

Question 12

Zolbetuximab

Answer 12

Claudin 18.2 (tight junction protein in gastric mucosa) –> cell death by ADCC, complement mediation

Question 13

Olaparib

Answer 13

PARP inhibition (BRCA mut) - inhibits poly(ADP‐ribose) polymerase, thereby blocking the repair of single‐strand DNA breaks

Question 14

Durvalumab

Answer 14

anti-PD1

Question 15

Tamoxifen

Answer 15

Selective (o)sterogen receptor modulator (SERM). Risk VTE, endometrial Ca

Question 16

Aromatase inhibitor

Answer 16

Reduces oestrogen biosynthesis. Risk: osteoporosis

Question 17

Abemaciclib, Palbociclib, Ribociclib

Answer 17

CD4/6 inhibitor (CKD-Rb1-E2F essential for progression through cell cycle (blocks phosphorylation of Rb))

Question 18

Alpelisib

Answer 18

alpha-specific PI3K inhibitor (endocrine resistant HR+/HER2- advanced breast ca)

Question 19

Trastuzumab deruxtecan

Answer 19

anti_HER2 IgG1 mAb + Topo I inh payload. ADR - N&V, diarrhoea, alopecia, ILD

Question 20

Sacituzumab govitecan

Answer 20

anti-TROP2 mAb + Topo I inh. Toxicity: myelosuppression, diarrhoea, alopecia.

Question 21

aprepitant

Answer 21

Neurokinin-1 (NK-1) receptor antagonist - used in chemotherapy-induced N&V. Substance P (emesis provoking) binds NK-1R (area postrema and the nucleus tractus solitarius)

Question 22

ondansetron

Answer 22

5-HT3 antagonist

Question 23

Olaparib

Answer 23

PARP inhibitor. N&V, anaemia.

Question 24

Docetaxel / Cabazitaxel

Answer 24

Stabilises microtubules during mitosis/interphase → mitotic arrest and cell death

Question 25

Abiraterone

Answer 25

Inhibits 17alpha-hydroxylase and c17, 20-lyase (androgen biosynthesis inhibitor)

Question 26

Enzalutamide and Apalutamide, Darolutamide

Answer 26

Androgen receptor inhibitor. Darolutamide - less BBB penetration (less CNS toxicity)

Question 27

Avelumab

Answer 27

PD-L1i in maintenance Tx for metastatic urothelial Ca/TCC

Question 28

Enfortumab Vedotin

Answer 28

Nectin-4 Ab conjugate - 3rd line Tx in mTCC. ADRs; Rash, hyperglycaemia, peripheral neuropathy

Question 29

Belimumab

Answer 29

B-lymphocyte stimulator (BLyS)-specific inhibitor in SLE for lupus nephritis (add-on therapy)

Question 30

Anifrolumab

Answer 30

Anti-type I IFN receptor in SLE